A pipeline of novel therapeutic potential for cancer patients

Cell type
Program
Discovery
Preclinical
IND-enabling
Phase 1
Pivotal
Partners
CAR-NKT
CD19/CD20
Multiple Myeloma Dual Target
Solid Tumors
CAR-γδ T
Autoimmune

Technology that spans the promise of both NK and T cell therapies by harnessing the power of rare, potent, cancer-fighting invariant T cells

Our Technology
Appia Bio's Technology Lab

If you're passionate about making waves in cell therapy, we'd love to hear from you